Search Results
Oct 17, 2025, 17:26 ET Eine Reise ins elegante Leben - LEPAS Global Journey of Elegant Driving (China Stop) erfolgreich abgeschlossen
900 Kilometern durch Shanghai, Suzhou, Moganshan, Xuancheng und Wuhu erlebten Medien, KOLs und Nutzer die herausragende Produktstärke des LEPAS L8- ein Panorama des eleganten Fahrens und eine anschauliche Interpretation seiner Positionierung als "Preferred Brand for Elegant Mobility Life".
More news about: Chery Group
Oct 17, 2025, 17:24 ET Un voyage vers une vie élégante - LEPAS Global Journey of Elegant Driving (China Stop) s'achève avec succès
Xuancheng et Wuhu, l'essai immersif a rassemblé les médias, les KOLs et les utilisateurs pour découvrir la force exceptionnelle du produit LEPAS L8- une vitrine panoramique de la conduite élégante et une interprétation vivante de son positionnement en tant que "Preferred Brand for Elegant Mobility
More news about: Chery Group
Oct 17, 2025, 15:56 ET Huawei presenta la soluzione AI WAN aggiornata con architettura incentrata sull'IA per stimolare la crescita degli operatori
minuti, utilizzando una knowledge base di 300.000 casi. Per l'identificazione dei rischi, MasOrange Spagna ha distribuito una rete di guida autonoma IP L4 basata sulla soluzione AI WAN di Huawei, riducendo il tempo medio di riparazione, abbassando al contempo i costi e migliorando l'efficienza.
More news about: Huawei
Oct 17, 2025, 15:50 ET Huawei onthult geüpgradede AI WAN-oplossing met AI-gerichte architectuur om de groei van carriers te stimuleren
een kennisbank met 300.000 gevallen de diagnosetijd van 45 naar 5 minuten teruggebracht. Voor de identificatie van risico's heeft MasOrange Spain een 'L4 IP autonomous driving network' geïmplementeerd dat door Huawei's AI WAN-oplossing wordt aangedreven, waardoor de gemiddelde reparatietijd wordt verkort,
More news about: Huawei
Oct 17, 2025, 15:43 ET Huawei stellt verbesserte KI-WAN-Lösung mit KI-zentrierter Architektur vor, um das Wachstum von Netzbetreibern zu fördern
Diagnosezeit mithilfe einer Wissensdatenbank mit 300.000 Fällen von 45 auf 5 Minuten verkürzen. Zur Risikoidentifizierung hat MasOrange Spain ein autonomes L4-IP-Netzwerk auf Basis der KI-WAN-Lösung von Huawei implementiert, wodurch die durchschnittliche Reparaturzeit verkürzt, die Kosten gesenkt und die Effizienz
More news about: Huawei
Oct 17, 2025, 15:31 ET Huawei představuje vylepšené řešení AI WAN s architekturou zaměřenou na AI, které podpoří růst operátorů
diagnostiky z 45 na 5 minut pomocí znalostní báze obsahující 300 000 případů. Pro identifikaci rizik nasadila společnost MasOrange Spain autonomní síť L4 IP poháněnou řešením AI WAN od společnosti Huawei. Takto zkrátila průměrnou dobu opravy, snížila náklady a zvýšila efektivitu. Summit
More news about: Huawei
Oct 17, 2025, 15:19 ET Huawei presenta una solución WAN de IA mejorada con una arquitectura centrada en IA
gracias a una base de conocimiento de 300.000 casos. Para la identificación de riesgos, MasOrange España implementó una red de conducción autónoma IP L4 con la solución AI WAN de Huawei, lo que redujo el tiempo medio de reparación, a la vez que redujo los costes y mejoró la eficiencia.
More news about: Huawei
Oct 17, 2025, 12:04 ET Life Time Named to Fortune 100 Fastest-Growing Companies List for 2025
lives through its more than 185 athletic country clubs across the U.S. and Canada, the complimentary and comprehensive Life Time app featuring its L•AI•C™ AI-powered health companion, and more than 30 iconic athletic events. Serving people ages 90 days to 90+ years, the Life Time ecosystem uniquely delivers
More news about: Life Time Group Holdings, Inc.
Oct 17, 2025, 12:00 ET Quilceda Creek releases rare library wines with goal of raising $250,000 for Cancer Research Institute
The campaign will include library Quilceda Creek Columbia Valley Cabernet Sauvignon in a vertical 6- and 12-bottle format, along with a 1.5L offering. This iconic Cabernet Sauvignon made history as the first wine outside California to earn a 100-point score from Robert Parker's Wine Advocate (2002
More news about: Quilceda Creek
Oct 17, 2025, 11:13 ET Henry Repeating Arms Expands Spirit of the Corps Rifle Series for Marine Corps' 250th Anniversary
Spirit of the Corps 250th Anniversary 2nd Edition .22 S/L/LR and the
More news about: Henry Repeating Arms
Oct 17, 2025, 10:30 ET METROCITY BANKSHARES, INC. REPORTS EARNINGS FOR THIRD QUARTER 2025
the risk of expansion into new geographic or product markets, (k) reputational risk and the reaction of the parties' customers to the Proposed Merger, (l) the Company's ability to successfully execute its various business strategies, including its ability to execute on potential acquisition opportunities,
More news about: MetroCity Bankshares, Inc.
Oct 17, 2025, 10:04 ET Equip Exposition Wins Greatest Trade Show Award in Trade Show Executive's Gold 100 Awards and Summit
https://www.dropbox.com/scl/fo/9y1vwq3bb0mbygm97qdlp/AHYbKswjawxMzcTl9graDkA?rlkey=l7mkynsauict4kwjyml746zxl&dl=0 Embeddable Videos:
More news about: Equip Exposition
Oct 17, 2025, 10:00 ET Boehringer's HERNEXEOS® demonstrated a 77% objective response rate in treatment-naïve patients with advanced HER2 (ERBB2)-mutant NSCLC
Psychological and Physical Symptoms in Newly Diagnosed Lung Cancer. Health Psychol. 2022 Jun; 41(6): 379–388. Andersen, B. L. et al. Newly diagnosed patients with advanced non-small cell lung cancer: A clinical description of those with moderate to severe depressive symptoms.
More news about: Boehringer Ingelheim
Oct 17, 2025, 08:37 ET J&L Marketing Ranks 10th on Louisville Business First's Fast 50 List and Celebrates a Year of Recognition
commitment that define J&L Marketing," Zabaneh added. "We are proud of what we have accomplished and excited to continue building on this momentum." About J&L Marketing Founded in 1991 and headquartered in Louisville, KY, J&L Marketing is a
More news about: J&L Marketing
Oct 17, 2025, 07:40 ET Spiber avvia una collaborazione con JNBY Group
Week La collaborazione è stata presentata anche allo SHAN FUTURE FORUM 2025, tenutosi l'11 ottobre 2025 durante la Shanghai Fashion Week e organizzato da yehyehyeh in collaborazione con il comitato della settimana della moda.
More news about: Spiber Inc.
Oct 17, 2025, 07:28 ET A Journey to Elegant Life -- LEPAS Global Journey of Elegant Driving (China Stop) Concludes Successfully
Moganshan, Xuancheng, and Wuhu, the immersive test drive gathered media, KOLs, and users to experience the outstanding product strength of the LEPAS L8—a panoramic showcase of elegant driving and a vivid interpretation of its positioning as the "Preferred Brand for Elegant Mobility Life."
More news about: Chery Group
Oct 17, 2025, 07:00 ET Boston Scientific Announces Agreement to Acquire Nalu Medical, Inc.
[email protected] i Hatheway, J., Hersel, A., Engle, M., Gutierrez, G., Khemlani, V., Kapural, L., Moore, G., Ajakwe, R., Trainor, D., Hah, J., Staats, P., Makous, J., Heit, G., Kottalgi, S., & Desai, M. J. (2024). Clinical study of a micro-implantable
More news about: Boston Scientific Corporation
Oct 17, 2025, 06:45 ET A Journey to Elegant Life -- LEPAS Global Journey of Elegant Driving (China Stop) Concludes Successfully
Moganshan, Xuancheng, and Wuhu, the immersive test drive gathered media, KOLs, and users to experience the outstanding product strength of the LEPAS L8—a panoramic showcase of elegant driving and a vivid interpretation of its positioning as the "Preferred Brand for Elegant Mobility Life."
More news about: Chery Group
Oct 17, 2025, 05:49 ET Adhesion Barrier Market 2025-30 Outlook Shows 7.5% CAGR as North America Leads Global Growth, Says Mordor Intelligence
Ambulatory Surgical Centers), and Geography (North America, Europe, Asia-Pacific). Baxter, Terumo, Getinge, LeMaitre Vascular, and W. L. Gore & Associates are the major companies operating in this market. Read more about companies active
More news about: Mordor Intelligence Private Limited
Oct 17, 2025, 05:42 ET Kelun-Biotech's Core product Trastuzumab Botidotin Approved for Marketing by NMPA for HER2-positive BC
significant advancement in the treatment of HER2-positive breast cancer. As China's first domestically developed HER2 ADC capable of broadly covering 2L+ HER2 BC patients, trastuzumab botidotin leverages its differentiated structural design to deliver superior efficacy while addressing unmet clinical needs
More news about: Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.
Oct 17, 2025, 05:36 ET Huawei Unveils Upgraded AI WAN Solution with AI-Centric Architecture to Boost Carrier Growth
China Mobile Guangdong cut diagnosis time from 45 to 5 minutes using a 300,000-case knowledge base. For risk identification, MasOrange Spain deployed an L4 IP autonomous driving network powered by Huawei's AI WAN Solution, reducing mean time to repair while lowering costs and improving efficiency.
More news about: Huawei
Oct 17, 2025, 05:15 ET Huawei Unveils Upgraded AI WAN Solution with AI-Centric Architecture to Boost Carrier Growth
China Mobile Guangdong cut diagnosis time from 45 to 5 minutes using a 300,000-case knowledge base. For risk identification, MasOrange Spain deployed an L4 IP autonomous driving network powered by Huawei's AI WAN Solution, reducing mean time to repair while lowering costs and improving efficiency.
More news about: Huawei
Oct 17, 2025, 05:05 ET Life Time Launches a New Era of Luxury Wellness at Iconic Prudential Center with October 17 Opening of Urban Athletic Country Club
healthy, happy lives through its 185 athletic country clubs across the U.S. and Canada, the complimentary and comprehensive Life Time app featuring its L•AI•C™ AI-powered health companion, and more than 30 iconic athletic events. Serving people ages 90 days to 90+ years, the Life Time ecosystem uniquely delivers
More news about: Life Time, Inc.
Oct 17, 2025, 02:58 ET I-Mab宣佈戰略轉型為全球生物科技平台型公司，擬赴港上市並更名為 「新橋生物（NovaBridge Biosciences）」
Bio的全球合作進行聯合開發，其中I-Mab作為牽頭方，與ABL Bio平分全球權益（大中華區和韓國除外）。 Ragistomig是一款抗PD-L1×4-1BB的雙特異性抗體。基於一期臨床數據，目前開展的1b期研究旨在擴大治療窗口，預計將在2026年下半年產生結果。該項目正與ABL Bio聯合開發。 Uliledlimab（抗CD73單抗）在腫瘤微環境中，CD73是腺甘介導免疫抑
More news about: I-Mab
Oct 16, 2025, 23:13 ET Wang Qunbin: Innovation-Driven, Fosun's Path to Globalization
of innovative drugs. HLX43, a PD-L1-targeting antibody-drug conjugate (ADC) is undergoing clinical studies for solid tumors such as non-small cell lung cancer and thymic carcinoma in countries including China, the United States, Japan, and Australia. Currently, no PD-L1 ADC has been approved globally,
More news about: Fosun